Other News To Note
Wednesday, October 17, 2012
BioLineRx Ltd., of Jerusalem, said it successfully completed the preclinical development of BL-8020, an orally available, interferon-free treatment for the hepatitis C virus and plans to start a Phase I/II safety and efficacy study for the compound in Europe during the first quarter of 2013.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.